Getting Organized on Abuse-Deterrent Opioids: FDA Calls For Volunteers Ahead of Oct. 30-31 Meeting
This article was originally published in RPM Report
Executive Summary
FDA is planning a two-day workshop on issues related to abuse-deterrent opioid formulations, and wants to hear unified presentations from the brand and generic industry. That is easier said than done.